These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 34943243)

  • 1. Therapeutic Effects of Fenofibrate Nano-Emulsion Eye Drops on Retinal Vascular Leakage and Neovascularization.
    Huang L; Liang W; Zhou K; Wassel RA; Ridge ZD; Ma JX; Wang B
    Biology (Basel); 2021 Dec; 10(12):. PubMed ID: 34943243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fenofibrate-Loaded Biodegradable Nanoparticles for the Treatment of Experimental Diabetic Retinopathy and Neovascular Age-Related Macular Degeneration.
    Qiu F; Meng T; Chen Q; Zhou K; Shao Y; Matlock G; Ma X; Wu W; Du Y; Wang X; Deng G; Ma JX; Xu Q
    Mol Pharm; 2019 May; 16(5):1958-1970. PubMed ID: 30912953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Therapeutic Effects of PPARα Agonist on Ocular Neovascularization in Models Recapitulating Neovascular Age-Related Macular Degeneration.
    Qiu F; Matlock G; Chen Q; Zhou K; Du Y; Wang X; Ma JX
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5065-5075. PubMed ID: 28980001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic effects of PPARα agonists on diabetic retinopathy in type 1 diabetes models.
    Chen Y; Hu Y; Lin M; Jenkins AJ; Keech AC; Mott R; Lyons TJ; Ma JX
    Diabetes; 2013 Jan; 62(1):261-72. PubMed ID: 23043158
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fenofibrate Inhibits Cytochrome P450 Epoxygenase 2C Activity to Suppress Pathological Ocular Angiogenesis.
    Gong Y; Shao Z; Fu Z; Edin ML; Sun Y; Liegl RG; Wang Z; Liu CH; Burnim SB; Meng SS; Lih FB; SanGiovanni JP; Zeldin DC; Hellström A; Smith LEH
    EBioMedicine; 2016 Nov; 13():201-211. PubMed ID: 27720395
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vascular permeability in retinopathy is regulated by VEGFR2 Y949 signaling to VE-cadherin.
    Smith RO; Ninchoji T; Gordon E; André H; Dejana E; Vestweber D; Kvanta A; Claesson-Welsh L
    Elife; 2020 Apr; 9():. PubMed ID: 32312382
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Peroxisome proliferator-activated receptor α protects capillary pericytes in the retina.
    Ding L; Cheng R; Hu Y; Takahashi Y; Jenkins AJ; Keech AC; Humphries KM; Gu X; Elliott MH; Xia X; Ma JX
    Am J Pathol; 2014 Oct; 184(10):2709-20. PubMed ID: 25108226
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Novel Eye Drop Formulation for Potential Treatment of Neovascular Age-Related Macular Degeneration.
    Huang WC; Cheng F; Chen CC; Kuo PH; Wang YJ; Yin SC; Tu CM; Wu MH; Wang WY; Chen SE
    Transl Vis Sci Technol; 2021 Dec; 10(14):23. PubMed ID: 34932116
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preclinical and phase 1A clinical evaluation of an anti-VEGF pegylated aptamer (EYE001) for the treatment of exudative age-related macular degeneration.
    Eyetech Study Group
    Retina; 2002 Apr; 22(2):143-52. PubMed ID: 11927845
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Blockade of VEGFR1 and 2 suppresses pathological angiogenesis and vascular leakage in the eye.
    Huang H; Shen J; Vinores SA
    PLoS One; 2011; 6(6):e21411. PubMed ID: 21731737
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic Effects of a Novel Agonist of Peroxisome Proliferator-Activated Receptor Alpha for the Treatment of Diabetic Retinopathy.
    Deng G; Moran EP; Cheng R; Matlock G; Zhou K; Moran D; Chen D; Yu Q; Ma JX
    Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):5030-5042. PubMed ID: 28979999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.
    Wang W; LeBlanc ME; Chen X; Chen P; Ji Y; Brewer M; Tian H; Spring SR; Webster KA; Li W
    Angiogenesis; 2017 Nov; 20(4):479-492. PubMed ID: 28447229
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathogenic role of diabetes-induced PPAR-α down-regulation in microvascular dysfunction.
    Hu Y; Chen Y; Ding L; He X; Takahashi Y; Gao Y; Shen W; Cheng R; Chen Q; Qi X; Boulton ME; Ma JX
    Proc Natl Acad Sci U S A; 2013 Sep; 110(38):15401-6. PubMed ID: 24003152
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PPARα-Dependent Effects of Palmitoylethanolamide Against Retinal Neovascularization and Fibrosis.
    Ye S; Chen Q; Jiang N; Liang X; Li J; Zong R; Huang C; Qiu Y; Ma JX; Liu Z
    Invest Ophthalmol Vis Sci; 2020 Apr; 61(4):15. PubMed ID: 32298438
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topical administration of a multi-targeted kinase inhibitor suppresses choroidal neovascularization and retinal edema.
    Doukas J; Mahesh S; Umeda N; Kachi S; Akiyama H; Yokoi K; Cao J; Chen Z; Dellamary L; Tam B; Racanelli-Layton A; Hood J; Martin M; Noronha G; Soll R; Campochiaro PA
    J Cell Physiol; 2008 Jul; 216(1):29-37. PubMed ID: 18330892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of Modified Low-Density Lipoproteins and Fenofibrate on an Outer Blood-Retina Barrier Model: Implications for Diabetic Retinopathy.
    Fu D; Yu JY; Connell AR; Hookham MB; McLeese RH; Lyons TJ
    J Ocul Pharmacol Ther; 2020 Dec; 36(10):754-764. PubMed ID: 33107777
    [No Abstract]   [Full Text] [Related]  

  • 17. FGF21 Administration Suppresses Retinal and Choroidal Neovascularization in Mice.
    Fu Z; Gong Y; Liegl R; Wang Z; Liu CH; Meng SS; Burnim SB; Saba NJ; Fredrick TW; Morss PC; Hellstrom A; Talukdar S; Smith LE
    Cell Rep; 2017 Feb; 18(7):1606-1613. PubMed ID: 28199833
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Potential of TAK-593 Ophthalmic Emulsion for the Treatment of Age-Related Macular Degeneration.
    Mori Y; Yamamoto A; Nakagawa A; Hikima T; Isowaki A
    Biol Pharm Bull; 2023 Jul; 46(7):921-928. PubMed ID: 37164692
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Photodynamic therapy with verteporfin for choroidal neovascularization in patients with diabetic retinopathy.
    Ladd BS; Solomon SD; Bressler NM; Bressler SB
    Am J Ophthalmol; 2001 Nov; 132(5):659-67. PubMed ID: 11704027
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Therapeutic regulation of VE-cadherin with a novel oligonucleotide drug for diabetic eye complications using retinopathy mouse models.
    Ting KK; Zhao Y; Shen W; Coleman P; Yam M; Chan-Ling T; Li J; Moller T; Gillies M; Vadas MA; Gamble JR
    Diabetologia; 2019 Feb; 62(2):322-334. PubMed ID: 30443753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.